Drug Information

Drug General Information
Drug ID
D07CAQ
Former ID
DIB001396
Drug Name
SAFINGOL
Synonyms
Kynac; Kynacyte; SPC-100270; Safingol < Rec INN; L-threo-Dihydrosphingosine; SPC-100271 (HCl); (2S,3S)-2-Aminooctadecane-1,3-diol
Drug Type
Small molecular drug
Indication Psoriasis [ICD9: 696; ICD10:L40] Phase 1 [521599], [531343]
Structure
Download
2D MOL

3D MOL
Formula
C18H40NO2+
Canonical SMILES
CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO
InChI
1S/C18H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h17-18,20-21H,2-16,19H2,1H3/t17-,18-/m0/s1
InChIKey
OTKJDMGTUTTYMP-ROUUACIJSA-N
CAS Number
CAS 15639-50-6
PubChem Compound ID
25202626
Target and Pathway
Target(s) Protein kinase C Target Info Inhibitor [530494]
References
Ref 521599ClinicalTrials.gov (NCT00084812) Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
Ref 531343A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2484-92.
Ref 530494The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.